IL301713A - Methods for treating dermatomyositis - Google Patents

Methods for treating dermatomyositis

Info

Publication number
IL301713A
IL301713A IL301713A IL30171323A IL301713A IL 301713 A IL301713 A IL 301713A IL 301713 A IL301713 A IL 301713A IL 30171323 A IL30171323 A IL 30171323A IL 301713 A IL301713 A IL 301713A
Authority
IL
Israel
Prior art keywords
dermatomyositis
fusion protein
muscle
binding
administered
Prior art date
Application number
IL301713A
Other languages
English (en)
Hebrew (he)
Inventor
Paul P Tamburini
Original Assignee
Alexion Pharma Inc
Paul P Tamburini
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc, Paul P Tamburini filed Critical Alexion Pharma Inc
Publication of IL301713A publication Critical patent/IL301713A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/28—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
IL301713A 2020-10-05 2021-10-05 Methods for treating dermatomyositis IL301713A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063087577P 2020-10-05 2020-10-05
PCT/US2021/053540 WO2022076388A1 (en) 2020-10-05 2021-10-05 Methods of treating dermatomyositis

Publications (1)

Publication Number Publication Date
IL301713A true IL301713A (en) 2023-05-01

Family

ID=81126239

Family Applications (1)

Application Number Title Priority Date Filing Date
IL301713A IL301713A (en) 2020-10-05 2021-10-05 Methods for treating dermatomyositis

Country Status (10)

Country Link
US (1) US20230357442A1 (https=)
EP (1) EP4225372A4 (https=)
JP (1) JP2023544409A (https=)
KR (1) KR20230084210A (https=)
CN (1) CN116472065A (https=)
AU (1) AU2021358027A1 (https=)
CA (1) CA3172994A1 (https=)
IL (1) IL301713A (https=)
MX (1) MX2023004034A (https=)
WO (1) WO2022076388A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116313071B (zh) * 2023-01-16 2023-09-08 南方医科大学南方医院 一种预测初诊皮肌炎患者发生快速进展型间质性肺病的风险模型的构建方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2794359A (en) * 1953-09-22 1957-06-04 Lyman Gun Sight Corp Automatic primer feed device
JP5809242B2 (ja) * 2010-04-21 2015-11-10 アッヴィ バイオテクノロジー リミテッド 治療薬の制御送達のための装着型自動注入装置
EP3511339B1 (en) * 2012-02-20 2025-04-09 IPC Research, LLC Polypeptides binding to human complement c5
CN108476328B (zh) * 2016-01-04 2021-04-20 瑞典爱立信有限公司 改进的网络记录设备
KR102806328B1 (ko) * 2017-07-11 2025-05-14 알렉시온 파마슈티칼스, 인코포레이티드 보체 성분 c5 또는 혈청 알부민에 결합하는 폴리펩티드 및 그의 융합 단백질
BR112021018456A2 (pt) * 2019-03-22 2021-11-23 Achillion Pharmaceuticals Inc Compostos farmacêuticos para o tratamento de distúrbios mediados por complemento
AU2022283254A1 (en) * 2021-05-25 2023-11-30 Alexion Pharmaceuticals, Inc. Kidney active fusion proteins and methods of treatment using the same
JP2024534083A (ja) * 2021-08-20 2024-09-18 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体代替経路阻害剤を用いて鎌状赤血球症又はベータサラセミアを治療する方法

Also Published As

Publication number Publication date
MX2023004034A (es) 2023-06-09
KR20230084210A (ko) 2023-06-12
CA3172994A1 (en) 2022-04-14
WO2022076388A1 (en) 2022-04-14
CN116472065A (zh) 2023-07-21
EP4225372A1 (en) 2023-08-16
US20230357442A1 (en) 2023-11-09
JP2023544409A (ja) 2023-10-23
AU2021358027A1 (en) 2023-05-11
EP4225372A4 (en) 2024-11-06

Similar Documents

Publication Publication Date Title
TWI761869B (zh) 包含抗cd47/pd-l1雙特異性抗體的製劑及其製備方法和用途
IL323697A (en) Activin receptor type IIA variants and methods of using them
TW201945031A (zh) 低ph藥物製劑
IL260753B2 (en) Pharmaceutical preparations containing constructs of bispecific antibodies that bind to antigen on target cell surfaces and CD3
CN108473566A (zh) 抗N3pGlu淀粉样蛋白β肽抗体及其用途
CN117024583A (zh) 抗N3pGlu淀粉状蛋白β肽抗体及其用途
CN104684929A (zh) 治疗血管疾病及其并发症
CN110960490A (zh) 一种抗egfr抗体偶联药物组合物及其用途
US20230173069A1 (en) Formulation comprising anti-il-23p19 antibody, method for preparing same and use thereof
CN113453719A (zh) 包含抗cd47抗体的制剂及其制备方法和用途
TW201439118A (zh) Ｂｍｐ－６抗體
US20230080706A1 (en) Recombinant fully human anti-tigit monoclonal antibody formulation, method for preparing same and use thereof
IL293367A (en) Pharmaceutical formulations and dosage regimens for antibodies to factor xi/xia
IL301713A (en) Methods for treating dermatomyositis
EP4257603A1 (en) Pharmaceutical composition comprising anti-connective tissue growth factor antibody
JP7809067B2 (ja) 抗セラミド抗体
WO2022111612A1 (zh) 包含抗tigit/pd-1双特异性抗体的制剂及其制备方法和用途
WO2025128839A1 (en) Methods for the treatment of thyroid eye disease with anti igf-1r antagonistic antibodies
US20260077041A1 (en) BISPECIFIC FUSION PROTEIN TARGETING TNF-a AND IL-17A, AND USE THEREOF
EP3207059A1 (en) Antibodies directed to angiopoietin-1 and angiopoietin-2 for ocular therapies
WO2023071953A1 (zh) 抗cd26抗体及其应用
JP2019505516A (ja) インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法
WO2025081130A1 (en) Use of anti-asc antibody in the treating of ocular disorders
WO2025166169A1 (en) Compositions, doses, and methods for treatment of c1s mediated diseases and disorders
CN117982437A (zh) 一种靶向冠状病毒的抗体制剂及其应用